🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation
Kimberly Morgan’s Post
More Relevant Posts
-
🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/GsLeHp 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/dqZJEH #oncology #oncologyresearch #ProductCitation
To view or add a comment, sign in
-
🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/R6k34m 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/ZU94BL #oncology #oncologyresearch #ProductCitation
To view or add a comment, sign in
-
Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. 🧬✨ The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules
To view or add a comment, sign in
-
𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"
To view or add a comment, sign in
-
Learn about the history and future of small molecule oncology drugs - big thanks to our friends at Lonza for the feature!
Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. 🧬✨ The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules
To view or add a comment, sign in
-
Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight
To view or add a comment, sign in
-
💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies
To view or add a comment, sign in
-
🌟 Exciting news: ExpreS2ion Biotechnologies announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer! 🎉 Read the news here: https://lnkd.in/dUgu2ZaX #Biotech #BreastCancerResearch #Innovation #ExpreS2ionBiotechnologies #BreastCancerVaccine #CancerVaccine #FightBreastCancer #CancerAwareness #CancerTreatment #HER2Positive #ClinicalTrials #MedicalResearch #VaccinesSaveLives
To view or add a comment, sign in
-
Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery. https://hubs.li/Q02pvCkq0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight
To view or add a comment, sign in
-
Simoa® technology enables ultra-sensitive detection of #cancer biomarkers, supporting research identifying early-stage cancers and predicting outcomes. Explore the full list of homebrew assays developed to support #oncology research: https://lnkd.in/eA5hedGb
To view or add a comment, sign in